Skip to main content
. 2017 Jan 9;292(8):3420–3432. doi: 10.1074/jbc.M116.764910

FIGURE 8.

FIGURE 8.

TGF-β1/Smad3 targets PP2A-AMPK-FoxO1 signaling. a and b, PP2A enzyme activity in TGF-β1- and SB431543-treated HepG2 cells (a) and in HepG2 cells treated with TGF-β1 with or without ShS3 (two independent experiments performed in triplicate) (b). c, effect of PP2A inhibitor OKA on Smad3-LKB1-AMPK-FoxO1 proteins with and without TGF-β1 and SB431542 treatments in HepG2 cells. d and e, PP2A enzyme activity (d) and mRNA expression of gluconeogenic genes (e) in HepG2 cells upon treatment with TGF-β1 and SB431542 with or without OKA (in triplicate). All values present here are averages, and error bars represent S.E. *, p = 0.05; **, p = <0.01.